Skip to main content

Table 1 Demographics and scores by sex of parent, subtype of disease and duration of methotrexate use

From: Improvement in medication education in a pediatric subspecialty practice

Characteristic n= 100 (%) Initial n= 67 (%) Follow-Up
Sex of parent1     
   Female 73 (73%) 77.3 ± 20.9 49 (73%) 93.5 ± 11.1
   Male 27 (27%) 71.9 ± 18.6 18 (27%) 93.3 ± 9.7
Diagnosis1     
   Oligoarticular: Persistent 34 (34%) 74.1 ± 21.2 21 (31%) 94.3 ± 11.2
   Oligoarticular: Extended 5 (5%) 64.0 ± 35.8 4 (6%) 95.0 ± 10.0
   Polyarticular: RF (-) 39 (39%) 81.0 ± 18.3 25 (38%) 96.0 ± 8.2
   Polyarticular: RF (+) 4 (4%) 75.0 ± 25.2 3 (4%) 93.3 ± 11.5
   Enthesitis-related 6 (6%) 76.7 ± 15.1 5 (7%) 88.0 ± 11.0
   Psoriatic 10 (10%) 70.0 ± 14.1 7 (11%) 91.4 ± 10.7
   Systemic 2 (2%) 60.0 ± 28.3 2 (3%) 70.0 ± 14.1
MTX duration, months1     
   2-6 26 (26%) 75.4 ± 18.2 14 (21%) 95.7 ± 11.6
   7-12 15 (15%) 74.7 ± 17.7 13 (20%) 89.2 ± 10.4
   13-24 21 (21% 81.9 ± 18.9 13 (20%) 92.3 ± 13.0
   25-36 14 (14%) 80.0 ± 24.8 9 (13%) 97.8 ± 6.7
   37-48 11 (11%) 72.7 ± 20.5 9 (13%) 95.6 ± 8.8
   >48 13 (13%) 66.2 ± 23.6 9 (13%) 91.1 ± 10.2
  1. 1The sex of parent, subtype of disease and MTX duration did not show a significant difference in questionnaire scores (Mann-Whitney U test used for statistical analyses). RF, rheumatoid factor; MTX, methotrexate.